title: Adult inguinoscrotal sarcomas: outcome analysis of 21 cases, systematic review of the literature and meta-analysis.
abstract: OBJECTIVE
  Inguinoscrotal sarcomas are exceedingly rare tumors. The aim of this study was to enable clinicians an easy and rapid access to the available information on this tumor entity.
  
  
  METHODS
  An updated series of 21 men treated for sarcoma of the inguinoscrotal region at our institution between 1992 and 2012 was analyzed, and a systematic review of the literature with meta-analysis of outcome data was performed. The review was focused on demographic data, survival rates, prognostic factors, sites of relapse and complete remissions or successful treatments for metastatic disease.
  
  
  RESULTS
  With only 38 %, the proportion of high-grade tumors in our sample was lower than reported in the literature and the 10-year relapse-free, disease-specific and overall survival rates were favorable with 77, 93 and 81 %. Beside our series, twelve studies including 345 patients were identified in the literature. The weighed mean 10-year relapse-free, disease-specific and overall survival rates were 63, 64 and 50 %. Only in patients with rhabdomyosarcoma, durable control of metastatic disease has been reported in more than one case (n = 4). Successful treatment in these cases consisted of a combination of complete surgical resection of metastatic lesions, subsequent chemotherapy and (optional) radiotherapy.
  
  
  CONCLUSIONS
  Overall, about two-thirds of inguinoscrotal sarcomas may be cured. In series with a predominance of low-grade tumors, the long-term survival rates in completely excised inguinoscrotal sarcomas may be as favorable as in testicular germ cell tumors. Life-long surveillance is advisable to detect late recurrences.
authors.affiliation: Department of Urology, University Hospital Carl Gustav Carus, Dresden University of Technology, Fetscherstrasse 74, 01304, Dresden, Germany, Michael.Froehner@uniklinikum-dresden.de.
authors.forename: Michael
authors.initials: M
authors.lastname: Froehner
authors.forename: Rainer
authors.initials: R
authors.lastname: Koch
authors.forename: Arndt
authors.initials: A
authors.lastname: Lossnitzer
authors.forename: Rebecca R
authors.initials: RR
authors.lastname: Schober
authors.forename: Markus
authors.initials: M
authors.lastname: Schuler
authors.forename: Manfred P
authors.initials: MP
authors.lastname: Wirth
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D015331:Cohort Studies; D018572:Disease-Free Survival; D005834:Genital Neoplasms, Male / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007264:Inguinal Canal / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant / Q000379:methods*; D012509:Sarcoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012611:Scrotum / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate